CVRx announces availability of additional data supporting long-term benefits of Barostim

April 15, 2024

https://www.globenewswire.com/news-release/2024/04/15/2862655/0/en/CVRx-announces-availability-of-additional-data-supporting-long-term-benefits-of-Barostim.html

BeAT-HF trial data published in the European Journal of Heart Failure and new abstracts presented at THT conference

MINNEAPOLIS, Minn., April 15, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ:CVRX) (“CVRx”), a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. These data highlight long-term sustained benefits of Barostim in heart failure patients with reduced ejection fraction.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.